All In Biotech

Drug Trial Radar · NCT05389449

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated With Danicopan in an Alexion-sponsored Clinical Study

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

80

Actual

Start

Oct 28, 2022

Primary completion

Aug 24, 2026

Study completion Aug 24, 2026

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • DanicopanDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEsTime frame: Up to 3 years

Locations

45 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Kansas City, Missouri

  • Research Site

    Long Island City, New York

  • Research Site

    Cleveland, Ohio

  • Research Site

    Dallas, Texas

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Lille, France

  • Research Site

    Paris, France

  • Research Site

    Pessac, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Athens, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Avellino, Italy

  • Research Site

    Bassano del Grappa, Italy

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Reggio Calabria, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Shibuya-ku, Japan

  • Research Site

    Tsukuba, Japan

  • Research Site

    Kota Kinabalu, Malaysia

  • Research Site

    Kuching, Malaysia

  • Research Site

    Miri, Malaysia

  • Research Site

    Gdansk, Poland

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

  • Research Site

    Badalona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Majadahonda, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.